However, this guidance applies exclusively to the oral tablet and not to any injectable GLP-1 formulations
Giannopolitis, N
In June 2021, the FDA approved a higher-dose formulation of semaglutidemarketed under the brand name Wegovyspecifically for chronic weight management in adults with obesity or those who are overweight and have at least one weight-related health condition, such as type 2 diabetes, high blood pressure, or high cholesterol
doi: 10.1056/NEJMoa1607141 Husain M, Bain SC, Jeppesen OK, et al
Later on, in the addiction cycle, relapse drinking after alcohol withdrawal is an important aspect of AUD, and this can be modeled using the alcohol deprivation test in rats (Sanchis-Segura and Spanagel, 2006)